Moreover, the data from the H460 xenograft experiment demonstrated that the combination treatment had the strongest tumor growth delay and induced cell death effects compared with the single treatment (Fig. 5), which indicated that AURKA target inhibition could suppress tumor growth and enhance irradiation sensitivity in vivo in the P53-competent cells. This evidence concerns the gene TP53 and neoplasm.